CN111991543A - Traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia and preparation method thereof - Google Patents
Traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia and preparation method thereof Download PDFInfo
- Publication number
- CN111991543A CN111991543A CN202010890615.1A CN202010890615A CN111991543A CN 111991543 A CN111991543 A CN 111991543A CN 202010890615 A CN202010890615 A CN 202010890615A CN 111991543 A CN111991543 A CN 111991543A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- severe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 238000009098 adjuvant therapy Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 19
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 19
- 235000008434 ginseng Nutrition 0.000 claims abstract description 19
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 18
- 244000223014 Syzygium aromaticum Species 0.000 claims abstract description 18
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims abstract description 18
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 18
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 17
- 235000008397 ginger Nutrition 0.000 claims abstract description 17
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 241001633680 Polygonatum odoratum Species 0.000 claims abstract description 14
- 241000208340 Araliaceae Species 0.000 claims description 18
- 241000234314 Zingiber Species 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000001154 acute effect Effects 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 8
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 7
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 4
- 244000037364 Cinnamomum aromaticum Species 0.000 claims 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims 1
- 229940107131 ginseng root Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 10
- 230000009471 action Effects 0.000 abstract description 7
- 230000007246 mechanism Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 230000001717 pathogenic effect Effects 0.000 description 7
- 208000000059 Dyspnea Diseases 0.000 description 6
- 206010013975 Dyspnoeas Diseases 0.000 description 6
- 206010010071 Coma Diseases 0.000 description 5
- 241000711573 Coronaviridae Species 0.000 description 5
- 206010013954 Dysphoria Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 208000028399 Critical Illness Diseases 0.000 description 4
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
- 208000008454 Hyperhidrosis Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000007667 floating Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 4
- 241000233866 Fungi Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229910052956 cinnabar Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229910052957 realgar Inorganic materials 0.000 description 3
- AIULWNKTYPZYAN-SFHVURJKSA-N (10)-Gingerol Chemical compound CCCCCCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 AIULWNKTYPZYAN-SFHVURJKSA-N 0.000 description 2
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 2
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 2
- AIULWNKTYPZYAN-UHFFFAOYSA-N 810gingerol Natural products CCCCCCCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 AIULWNKTYPZYAN-UHFFFAOYSA-N 0.000 description 2
- SCCDQYPEOIRVGX-UHFFFAOYSA-N Acetyleugenol Chemical compound COC1=CC(CC=C)=CC=C1OC(C)=O SCCDQYPEOIRVGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 244000303379 Styrax officinalis Species 0.000 description 2
- 235000001361 Styrax officinalis Nutrition 0.000 description 2
- WQLVFSAGQJTQCK-CAKNJAFZSA-N Yamogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 WQLVFSAGQJTQCK-CAKNJAFZSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229930016183 alpha-curcumene Natural products 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 2
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000019382 gum benzoic Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005399 mechanical ventilation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-VUFVRDRTSA-N (20R)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-VUFVRDRTSA-N 0.000 description 1
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- BRPWRSWAXHWEPS-UHFFFAOYSA-N 2,5-dibromopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CN=C1Br BRPWRSWAXHWEPS-UHFFFAOYSA-N 0.000 description 1
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 1
- RDAFNSMYPSHCBK-UHFFFAOYSA-N 3-phenylprop-2-en-1-amine Chemical compound NCC=CC1=CC=CC=C1 RDAFNSMYPSHCBK-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 101150060184 ACHE gene Proteins 0.000 description 1
- 102000017919 ADRB2 Human genes 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 239000009715 Angong Niuhuang Pill Substances 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- -1 Bornyl levulinate Chemical compound 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- RZMVZGBWRVWLTB-UHFFFAOYSA-N CC1=C(C(=CC(=C1)CC=C)OC)O.CC1=C(C(=CC(=C1)CC=C)OC)O Chemical compound CC1=C(C(=CC(=C1)CC=C)OC)O.CC1=C(C(=CC(=C1)CC=C)OC)O RZMVZGBWRVWLTB-UHFFFAOYSA-N 0.000 description 1
- MIGXRXJVZMOHES-UHFFFAOYSA-N CC1CCC2C(C)(C)C3CC12CC=C3C.CC3CCC1C(C)(C)C2CC31CC=C2C Chemical compound CC1CCC2C(C)(C)C3CC12CC=C3C.CC3CCC1C(C)(C)C2CC31CC=C2C MIGXRXJVZMOHES-UHFFFAOYSA-N 0.000 description 1
- 102000017927 CHRM1 Human genes 0.000 description 1
- 102000017925 CHRM3 Human genes 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 102000017696 GABRA1 Human genes 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- UZIOUZHBUYLDHW-MSJHMJQNSA-N Ginsenoside Rf Natural products O([C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@@H](O)C2)[C@@H]([C@@](O)(CC/C=C(\C)/C)C)CC3)C1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 UZIOUZHBUYLDHW-MSJHMJQNSA-N 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101000893331 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-1 Proteins 0.000 description 1
- 101000782981 Homo sapiens Muscarinic acetylcholine receptor M1 Proteins 0.000 description 1
- 101000928919 Homo sapiens Muscarinic acetylcholine receptor M3 Proteins 0.000 description 1
- 101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
- 101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 101000655897 Homo sapiens Serine protease 1 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100032491 Serine protease 1 Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- APEJMQOBVMLION-UHFFFAOYSA-N cinnamic acid amide Natural products NC(=O)C=CC1=CC=CC=C1 APEJMQOBVMLION-UHFFFAOYSA-N 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- UZIOUZHBUYLDHW-XUBRWZAZSA-N ginsenoside Rf Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@H]2C[C@@H](O)[C@H]3[C@@]([C@@]2(C1)C)(C)CC[C@@H]3[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZIOUZHBUYLDHW-XUBRWZAZSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- IUSBVFZKQJGVEP-SNAWJCMRSA-N isoeugenol acetate Chemical compound COC1=CC(\C=C\C)=CC=C1OC(C)=O IUSBVFZKQJGVEP-SNAWJCMRSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940058352 levulinate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000009112 niuhuang Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- QXKXDIKCIPXUPL-UHFFFAOYSA-N sulfanylidenemercury Chemical group [Hg]=S QXKXDIKCIPXUPL-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- RXGUTQNKCXHALN-BJMVGYQFSA-N trans-N-p-coumaroyl tyramine Chemical compound C1=CC(O)=CC=C1CCNC(=O)\C=C\C1=CC=C(O)C=C1 RXGUTQNKCXHALN-BJMVGYQFSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for severe acute pneumonia, which is prepared from the following raw materials in parts by weight: 0.5-5 parts of ginseng, 1-15 parts of cordyceps militaris, 0.2-5 parts of cinnamon, 1-12 parts of polygonatum odoratum, 1-3 parts of clove and 1-10 parts of dried ginger. And a preparation method of the traditional Chinese medicine composition for severe adjuvant therapy of the new coronary pneumonia is provided. The research result of the formula component-target point-pharmacological action mechanism network of the traditional Chinese medicine composition for the adjuvant therapy of severe new coronary pneumonia is consistent with the link of the main treatment disease, and the modern precise medical principle is met. Meanwhile, the product has low cost and meets the requirement of industrialized production.
Description
Technical Field
The invention belongs to the technical field of health care products, and particularly relates to a traditional Chinese medicine composition for severe adjuvant therapy of neocoronary pneumonia and a preparation method thereof.
Background
The novel Coronavirus pneumonia (COVID-19, New CoV pneumonia) is an Acute infectious disease caused by a newly discovered Coronavirus (Severe Acute Respiratory Syndrome-Coronavir-2, SARS-CoV-2) infection. The disease is taken as an acute respiratory infectious disease and is incorporated into a B infectious disease specified in the infection prevention and treatment law of the people's republic of China, and is managed according to the A infectious disease. By adopting a series of preventive control and medical treatment measures, the rising momentum of the epidemic situation in China is restrained. With the deepening of clinical manifestation and pathological understanding of the disease and the accumulation of diagnosis and treatment experiences, new technologies and new methods for prevention, detection and treatment are urgently needed to be developed and applied in order to further strengthen early diagnosis and early treatment of the disease, improve the cure rate and reduce the death rate.
According to the diagnosis and treatment scheme for novel coronavirus pneumonia (trial seventh edition), the patients with severe symptoms are classified into light type, ordinary type, heavy type and dangerous type, wherein respiratory failure occurs in critically ill patients, and other organ failure may occur. The traditional Chinese medicine believes that the disease belongs to the category of epidemic diseases, namely qi of exogenous epidemic crime. When the treatment is not timely, the state of the disease is easy to be transferred to the critical stage, and the healthy qi of the patient does not enemy the pathogenic factors, so that the pathogenic factors are exuberant and weak, and the internal block and the external collapse occur. The clinical manifestations are coma, dysphoria, dyspnea with aggravation, cyanosis of lips, dark complexion, burning or cold hands and feet, purple and dark tongue, yellow, thick and dry coating, and superficial, large and rootless pulse.
The prescription of the new coronary pneumonia diagnosis and treatment plan comprises storax pill and AngongNiuhuang pill, and contains Cinnabaris and Realgar. The main component of the cinnabar is mercuric sulfide, chronic mercury poisoning can be caused after long-term administration, liver and kidney damage is caused, and the cinnabar can directly damage a central nervous system through a blood brain barrier. When researchers administer storax pills to rats for 10 days, the creatinine value tends to increase, and if the rats are taken overtime, the result may exceed the normal value range, even pathological damage is generated. Realgar in the Angong Niuhuang Wan belongs to one of toxic traditional Chinese medicines containing arsenic in the medical toxic medicine management method, and the arsenic salt can be accumulated in liver and kidney tissues and has organ, nerve, heredity and cytotoxicity according to literature reports. Therefore, both cinnabar and realgar have certain toxicity, and are not suitable for being taken too much or for a long time, thereby limiting the application and curative effect of the prescription. Moreover, the pill has slow onset speed and is not beneficial to rescue of critical illness.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia and a preparation method thereof.
The invention provides a traditional Chinese medicine composition for severe acute pneumonia, which is prepared from the following raw materials in parts by weight:
0.5 to 5 parts of ginseng,
1-15 parts of cordyceps militaris,
0.2 to 5 parts of cinnamon,
1-12 parts of polygonatum odoratum,
1-3 parts of clove, namely,
1-10 parts of dried ginger.
And a preparation method of the traditional Chinese medicine composition for severe adjuvant therapy of the new coronary pneumonia, which comprises the following steps:
weighing traditional Chinese medicine raw materials according to the proportion of the traditional Chinese medicine composition for adjuvant therapy of severe neocoronary pneumonia, mixing cinnamon, radix polygonati officinalis, clove and dried ginger, adding 5-20 times of water by mass, soaking for 15-60 minutes, heating, refluxing, extracting for 0.5-2 hours, and filtering with 80-200 meshes to obtain a first extracting solution;
adding 5-20 times of water by mass into the medicine residues, performing reflux extraction for 0.5-2 hours, and filtering by 80-200 meshes to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding Ginseng radix and Cordyceps militaris to obtain the Chinese medicinal composition for adjuvant treatment of severe acute coronary pneumonia.
The traditional Chinese medicine composition for severe adjuvant therapy of the new coronary pneumonia is safe and effective, wherein the ginseng can greatly tonify primordial qi, the cinnamon can tonify primordial qi and activate yang, the polygonatum odoratum can nourish yin and moisten lung, the clove can warm middle-jiao and assist yang, and the dried ginger can warm middle-jiao and restore yang and activate pulse, so that the functions of tonifying qi and dredging orifices and restoring yang and rescuing the patient from collapse are achieved, the traditional Chinese medicine composition is used for a severe patient of the new coronary pneumonia with internal block and external collapse, is an accurate medicine-food homologous product with clear effective components and relatively clear action targets, and meets the clinical requirements and the needs of people for severe adjuvant.
Drawings
Fig. 1 is a network diagram of the traditional Chinese medicine raw material-active ingredient-action target point association of the traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia provided by the embodiment of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The embodiment of the invention provides a traditional Chinese medicine composition for severe acute pneumonia, which is prepared from the following raw materials in parts by weight:
0.5 to 5 parts of ginseng,
1-15 parts of cordyceps militaris,
0.2 to 5 parts of cinnamon,
1-12 parts of polygonatum odoratum,
1-3 parts of clove, namely,
1-10 parts of dried ginger.
The traditional Chinese medicine composition for adjuvant therapy of severe neocoronary pneumonia consists of extracts of ginseng, cinnamon, cordyceps militaris, polygonatum odoratum, clove and dried ginger, and is mainly used for patients with severe neocoronary pneumonia (internal block and external collapse), dyspnea, frequent asthma or assisted ventilation, coma, dysphoria, sweating, cold limbs, dark purple tongue, thick and greasy or dry tongue coating, and floating and large pulse without root clinically. The cyber pharmacological research screens 85 related active ingredients, mainly comprising Ginsenoside ingredients (3R) -Protopanaxadiol, (20S) -Protopanaxadiol, (20R) -Protopanaxadiol, Ginsenoside rh2, Ginsenoside rf, Ginsenoside Rg1, Ginsenoside Rb1, Ginsenoside-Rd, Ginsenoside Re; alpha-cedrene (alpha-cedrene), cinnamylamide acid (cinnamate), cinnamylaldehyde; n-coumaroyltyramine, Yamogenin, zoomicacid (palmitoleic acid); eugeninol (eugenol), Methyleugenol (methyl eugenol), acetoisoeugenol (acetyl eugenol); 6-Gingerol (6-Gingerol), 6-shogaol (6-shogaol), 1,8-cineole (1, 8-cineole), L-Bornyl acetate (Bornyl levulinate), 10-Gingerol (10-Gingerol), alpha-Curcumene (alpha-Curcumene); cordycepin, Adenosine, ergosterol, Cordycepic acid, beta-D-Galactoside, etc. Target prediction of active ingredients was performed to screen 196 targets, mainly including PTGS2, ESR1, F2, DPP4, AR, NOS2, PRSS1, PTGS1, ACHE, CA2, CHRM1, PPARG, ADRB2, CDK2, GABRA1, CHRM3, NOS3, MAPK14, GSK3B, etal. 196 targets were analyzed by KEGG, which was mainly enriched in HIF-1signaling pathway, cGMP-PKG signaling pathway, Hepatitis B, Neurotrophin signaling pathway, Calcium signaling pathway, PI3K-Akt signaling pathway, TNF signaling pathway, VEGF signaling pathway, Influnza A, etc. As shown in Table 1, a large number of pharmacological research results show that the formula has the functions of antishock, strengthening heart and lung functions, improving peripheral blood circulation, resisting platelet aggregation, anticoagulation, anti-infection and antivirus function activities, and is used for treating dyspnea caused by internal occlusion and external collapse, frequent asthma or mechanical ventilation, coma, dysphoria, sweating, cold limbs, purple dark tongue, thick and greasy or dry tongue coating, and floating and large pulse without root.
Preferably, the raw materials for preparing the traditional Chinese medicine composition for the severe adjuvant therapy of the new coronary pneumonia further comprise 1-10 parts of trehalose, and preferably 5-7 parts of trehalose.
More preferably, the traditional Chinese medicine composition for severe acute coronary pneumonia adjuvant therapy is prepared from the following raw materials in parts by weight: 2-4 parts of ginseng, 1-3 parts of cordyceps militaris, 2-4 parts of cinnamon, 9-11 parts of polygonatum odoratum, 2-3 parts of clove and 4-6 parts of dried ginger.
More specifically, the traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia is prepared from the following raw materials in parts by weight: 3 parts of ginseng, 2 parts of cordyceps militaris, 3 parts of cinnamon, 10 parts of polygonatum odoratum, 3 parts of clove and 5 parts of dried ginger.
The specific functions of the components are shown in the table 1:
TABLE 1
The traditional Chinese medicine composition for adjuvant therapy of severe new coronary pneumonia has the characteristics of definite curative effect, convenience in use, clear action target and pharmacological effect, wide raw material source, low cost, excellent preparation, high patient compliance and the like, is suitable for symptoms of dyspnea caused by internal block and external collapse, frequent asthma, coma, dysphoria, sweating, cold limbs, purple dark tongue, thick and greasy or dry tongue coating, floating and large pulse without root and the like, and can effectively improve clinical symptoms of severe new coronary pneumonia patients.
The first place of the new coronary pneumonia in China is Wuhan in Huazhong, and when the years are handed over from Hei to Heng, the climate is cloudy and rainy, and damp pathogen becomes a main pathogenic factor. Dampness is a yin pathogen, which is turbid in nature, sticky and descending, and tends to attack yin position, impairing yang qi and blocking qi movement. The combination of pathogenic factors and dampness causes a lot of variability to the disease, which makes the disease more lingering and difficult to cure. Although pathogenic qi enters through the mouth and nose, it directly enters the upper energizer and stagnates in the lung vessels, obstructing the spleen qi and causing disorder of qi movement. According to the clinical classification of the diagnosis and treatment of novel coronavirus pneumonia (trial seventh edition), one of the following cases is critical: (1) respiratory failure occurs and mechanical ventilation is required; (2) the onset of shock; (3) when other organs are in failure, ICU monitoring treatment is needed. If the condition is further developed, pulmonary edema and alveolar transparent membrane are formed, ventilation failure occurs, even high-concentration oxygen is inhaled, the high-concentration oxygen cannot be corrected, severe anoxia and carbon dioxide retention are accompanied, acidosis is combined, and finally cardiac arrest can be caused. At this stage, chills, high fever, shortness of breath, restlessness and mental status can be changed. The traditional Chinese medicine composition for adjuvant therapy of severe new coronary pneumonia can effectively relieve dyspnea caused by internal block and external collapse, frequent asthma, coma, dysphoria, sweating, cold limbs, dark purple tongue, thick and greasy or dry fur, floating pulse, no root and other symptoms by tonifying qi and dredging orifices and restoring yang for rescuing, and is used for adjuvant therapy and treatment of patients with severe new coronary pneumonia. Convenient administration, quick absorption, quick action, safety and reliability, and is suitable for clinical critical illness. The medicinal materials used by the traditional Chinese medicine composition for the adjuvant therapy of severe neocoronary pneumonia are safe and reliable, and can supplement and regulate the functions of a human body in time by invigorating qi, warming middle energizer, dredging resuscitation, reviving yang and rescuing from collapse, so that qi can be supplemented and removed, and vital qi can be recovered. The effective components are clear, the action target point network is clear, the physiological/pathological process of participation action is clear, as shown in figure 1, and the research result of the component-target point-pharmacological action mechanism network of the formula conforms to the requirement of critical illness state.
The embodiment of the invention also provides a preparation method of the traditional Chinese medicine composition for severe acute coronary pneumonia adjuvant therapy, which comprises the following steps:
weighing traditional Chinese medicine raw materials according to the proportion of the traditional Chinese medicine composition for adjuvant therapy of severe neocoronary pneumonia, mixing cinnamon, radix polygonati officinalis, clove and dried ginger, adding 5-20 times of water by mass, soaking for 15-60 minutes, heating, refluxing, extracting for 0.5-2 hours, and filtering with 80-200 meshes to obtain a first extracting solution;
adding 5-20 times of water by mass into the medicine residues, performing reflux extraction for 0.5-2 hours, and filtering by 80-200 meshes to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding Ginseng radix and Cordyceps militaris to obtain the Chinese medicinal composition for adjuvant treatment of severe acute coronary pneumonia.
Preferably, mixing and mixing cinnamon, polygonatum odoratum, clove and dried ginger, adding 8-15 times of water by mass, soaking for 20-40 minutes, heating, refluxing and extracting for 0.5-2 hours, and filtering with 100 meshes to obtain a first extracting solution;
adding 8-15 times of water by mass into the medicine residues, heating, refluxing and extracting for 0.5-2 hours, and filtering by a 100-mesh sieve to obtain a second extracting solution.
Preferably, the ginseng and the cordyceps militaris are subjected to superfine grinding and then used.
Specifically, the first extract and the second extract are combined, and the mixture is concentrated under reduced pressure at 70 ℃ until the relative density is about 1.07, so as to obtain a concentrated solution for later use; adding maltodextrin into the concentrated solution, stirring, and spray drying (nozzle inlet air temperature is 150 deg.C, and outlet air temperature is 80 deg.C) to obtain extract powder. Adding superfine powder of Ginseng radix and scarlet caterpiller fungus and trehalose into the extract powder, and mixing; subpackaging with 10g per bag to obtain the solid beverage.
Or adding superfine powder of Ginseng radix and scarlet caterpiller fungus and trehalose into the above extract powder, adding proper food materials and adjuvants such as mannan-oligosaccharide, granulating with 85% ethanol, drying at 70 deg.C, grading, and tabletting; or dry granulating or directly tabletting with appropriate adjuvants such as maltodextrin, corn starch, wheat flour, and protein powder, and making into appropriate tablet.
The traditional Chinese medicine composition for adjuvant therapy of severe neocoronary pneumonia can be prepared by carrying out reflux extraction on 0.5-5 parts of ginseng, 1-15 parts of cordyceps militaris, 0.2-5 parts of cinnamon, 1-12 parts of polygonatum odoratum, 1-3 parts of clove and 1-10 parts of dried ginger by 20 times of water twice, merging filtrates, carrying out reduced pressure concentration at 70 ℃ until the relative density is about 1.07, adding a flavoring agent preservative and the like, uniformly stirring, centrifuging, preparing a clear liquid, subpackaging, and preparing oral liquid, a mixture, a liquid beverage and other forms.
The final form of the product can be various, including powder, granule, tablet, honeyed pill, soft extract, oral liquid, syrup, etc. In the preparation process, the drying mode can be spray drying, vacuum drying, freeze drying and the like; the granulation method can be dry granulation, wet granulation, one-step granulation and the like. Preferably, the concentrated solution is dried under reduced pressure, dried by spraying, and quickly dried to obtain powder, so that damage to various components is reduced, and support is provided for effectiveness of the product.
By adopting the method acceptable by relevant laws and regulations of pharmacy, food, health care products and the like, the traditional Chinese medicine components of the traditional Chinese medicine composition for the severe adjuvant therapy of the new coronary pneumonia can be extracted, concentrated, dried or crushed, further processed into products, the effective components of the compound are reserved, and the products are prepared into suitable administration forms (including dosage forms such as granules, powder, oral liquid, tablets and the like) or food forms such as tabletting candies, meal powder, solid beverages and the like, so that the requirements of the market on relevant products are met, and the invention belongs to the protection scope.
The following describes the above-mentioned Chinese medicinal composition for severe acute coronary pneumonia and its preparation method by means of specific formulation and preparation process examples.
Example 1:
weighing the traditional Chinese medicine raw materials according to the proportion of the traditional Chinese medicine composition for the adjuvant therapy of severe neocoronary pneumonia, mixing 6kg of cinnamon, 20kg of polygonatum odoratum, 6kg of clove and 10kg of dried ginger, adding 620L of water for soaking for 30 minutes, heating, refluxing, extracting for 1 hour, and filtering with 100 meshes to obtain a first extracting solution;
adding 620L of water into the residue, reflux-extracting for 1 hr, and filtering with 100 mesh sieve to obtain a second extractive solution;
mixing the first extractive solution and the second extractive solution, concentrating at 70 deg.C under reduced pressure to relative density of about 1.07 to obtain concentrated solution, adding 6kg Ginseng radix and 4kg scarlet caterpiller fungus, and 6kg trehalose, and mixing; subpackaging with 10g per bag to obtain the solid beverage.
Example 2:
the solid beverage prepared by the preparation method of the traditional Chinese medicine composition for the intensive adjuvant therapy of the new coronary pneumonia is taken by 10 patients infected with the new coronary pneumonia in the intensive stage every day for two weeks without any adverse reaction, and the disease of 5 patients is relieved.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (8)
1. The traditional Chinese medicine composition for severe acute neocoronary pneumonia adjuvant therapy is characterized by being prepared from the following raw materials in parts by weight:
0.5 to 5 parts of ginseng,
1-15 parts of cordyceps militaris,
0.2 to 5 parts of cinnamon,
1-12 parts of polygonatum odoratum,
1-3 parts of clove, namely,
1-10 parts of dried ginger.
2. The traditional Chinese medicine composition for severe acute neocoronary pneumonia treatment of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:
2-4 parts of ginseng,
1-3 parts of cordyceps militaris,
2-4 parts of cinnamon, namely cassia bark,
9-11 parts of polygonatum odoratum,
2-3 parts of clove, namely,
and 4-6 parts of dried ginger.
3. The traditional Chinese medicine composition for severe acute neocoronary pneumonia treatment of claim 1, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight:
3 parts of ginseng, namely ginseng root,
2 parts of cordyceps militaris (L.) Link,
3 parts of cinnamon, namely cinnamon, wherein,
10 parts of radix polygonati officinalis,
3 parts of clove, namely clove,
5 parts of dried ginger.
4. The traditional Chinese medicine composition for the adjuvant therapy of the middle stage of neocoronary infection according to claim 1, wherein the raw materials for preparing the traditional Chinese medicine composition further comprise trehalose.
5. A preparation method of a traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia is characterized by comprising the following steps:
weighing the raw materials according to the weight parts of the traditional Chinese medicine composition for adjuvant therapy of middle stage neocoronal infection according to any one of claims 1 to 3, mixing cinnamon, polygonatum odoratum, clove and dried ginger, adding 5-20 times of water by mass, soaking for 15-60 minutes, heating and refluxing for extraction for 0.5-2 hours, and filtering with 80-200 meshes to obtain a first extract;
adding 5-20 times of water by mass into the medicine residues, performing reflux extraction for 0.5-2 hours, and filtering by 80-200 meshes to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding Ginseng radix and Cordyceps militaris to obtain the Chinese medicinal composition for adjuvant treatment of severe acute coronary pneumonia.
6. The method for preparing a Chinese medicinal composition for adjuvant treatment of severe neocoronary pneumonia according to claim 5, wherein cinnamon, polygonatum odoratum, clove and dried ginger are mixed, and the mixture is soaked in water in an amount of 8-15 times by mass for 20-40 minutes.
7. The preparation method of the traditional Chinese medicine composition for severe acute coronary pneumonia according to claim 5, wherein 8-15 times of water by mass is added into the medicine residue.
8. The method for preparing a Chinese medicinal composition for adjuvant treatment of severe coronary pneumonia according to claim 5, wherein the trehalose is added after Ginseng radix and Cordyceps militaris are added.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020106989484 | 2020-07-17 | ||
| CN202010698948 | 2020-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111991543A true CN111991543A (en) | 2020-11-27 |
Family
ID=73466293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010890615.1A Pending CN111991543A (en) | 2020-07-17 | 2020-08-29 | Traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111991543A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113144179A (en) * | 2020-03-27 | 2021-07-23 | 广东天普生化医药股份有限公司 | Application of ulinastatin in preparing medicine for preventing and treating severe coronavirus pneumonia |
| CN113244275A (en) * | 2021-07-02 | 2021-08-13 | 上海市公共卫生临床中心 | Application of cordyceps militaris medicinal composition in preparation of preparation for preventing and/or treating neocorona and resisting respiratory viruses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111110824A (en) * | 2020-03-26 | 2020-05-08 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Medicinal composition for strengthening body resistance and rescuing lung and application thereof |
-
2020
- 2020-08-29 CN CN202010890615.1A patent/CN111991543A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111110824A (en) * | 2020-03-26 | 2020-05-08 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Medicinal composition for strengthening body resistance and rescuing lung and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 无: "新冠肺炎诊疗方案治疗药物信息汇编（ 第一版）", 《中南药学》 * |
| 武蕾: "《呼吸内科中西医诊疗学》", 31 January 2018 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113144179A (en) * | 2020-03-27 | 2021-07-23 | 广东天普生化医药股份有限公司 | Application of ulinastatin in preparing medicine for preventing and treating severe coronavirus pneumonia |
| CN113244275A (en) * | 2021-07-02 | 2021-08-13 | 上海市公共卫生临床中心 | Application of cordyceps militaris medicinal composition in preparation of preparation for preventing and/or treating neocorona and resisting respiratory viruses |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200506723B (en) | Composition for treating hepatitis C | |
| CN111991543A (en) | Traditional Chinese medicine composition for severe adjuvant therapy of new coronary pneumonia and preparation method thereof | |
| CN103405697A (en) | Medicament for treating pulmonary tuberculosis | |
| CN101934032B (en) | Chinese medicinal compound external preparation for treating diabetes and preparation method and application thereof | |
| CN103550477B (en) | Medicament for treating herpes zoster | |
| CN114712478A (en) | Traditional Chinese medicine composition and preparation for treating intestinal diseases and preparation method thereof | |
| CN112138133A (en) | Pharmaceutical composition for preventing and/or treating novel coronavirus pneumonia and preparation method and application thereof | |
| CN105381015A (en) | Traditional Chinese medicine composition with anti-depression function and preparation method thereof | |
| CN108743757A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating insomnia | |
| CN109125699A (en) | Application of the Xiao Chaihu Tang in preparation treatment hepatic encephalopathy drug | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN108553554A (en) | A kind of suppository and preparation method thereof for treating fever in children, palpitation with fear uneasiness, lung heat many coughs of phlegm | |
| CN114259523B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating cough variant asthma | |
| CN103735793B (en) | A kind ofly treat Chinese medicine of numb limbs and tense tendons after diabetes patient's apoplexy and preparation method thereof | |
| TWI825996B (en) | Compositions for treating diseases and/or symptoms caused by the new coronavirus | |
| CN102225082A (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN113117009A (en) | Traditional Chinese medicine preparation for treating asthma and preparation method thereof | |
| CN1291722C (en) | Use of oligoxylose in preparing medicine for treating diabetes | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof | |
| CN117503898A (en) | Traditional Chinese medicine composition for treating asthma and application thereof | |
| CN109954055A (en) | A kind of pharmaceutical composition that treating bronchial asthma and preparation method and purposes | |
| TW202404623A (en) | Compositions for treating diseases and/or symptoms caused by the new coronavirus | |
| CN107875223A (en) | A kind of Chinese medicine composition for treating hepatitis and preparation method thereof | |
| CN109498786A (en) | A kind of invigorating kidney, promoting blood circulation composition and preparation method thereof | |
| CN114159488A (en) | Pharmaceutical composition and application thereof in field of improving anoxia tolerance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |